Muhammet Akyuz1, Pınar Yazici1, Cem Dural1, Hakan Yigitbas1, Alexis Okoh1, Emre Bucak1, Michael McNamara2, Arun Singh3, Eren Berber4. 1. Departments of Endocrine and General Surgery, Cleveland Clinic, 9500 Euclid Avenue/F20, Cleveland, OH, 44195, USA. 2. Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA. 3. The Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Departments of Endocrine and General Surgery, Cleveland Clinic, 9500 Euclid Avenue/F20, Cleveland, OH, 44195, USA. berbere@ccf.org.
Abstract
BACKGROUND: Although uveal melanoma is a rare disease, its metastasis to the liver is associated with a poor survival. The aim of this study is to analyze the survival after surgical treatment of uveal melanoma metastases to the liver. METHODS: Within 15 years, 44 patients with uveal melanoma metastases to the liver were managed at a single center. Medical records were reviewed to identify patients who underwent surgical treatment of their liver disease. Clinical and oncologic results were compared to those patients who were managed otherwise. T test, Chi-square test, and Kaplan-Meier survival analyses were performed. RESULTS: There were 16 patients who underwent surgical treatment (laparoscopic liver resection, n = 2 and laparoscopic radiofrequency ablation, n = 14), compared to 28 patients who received systemic therapy. The groups were similar regarding demographics and size of primary tumor. The interval between diagnoses of primary tumor and liver metastases was longer for the surgical group (58 vs 22 months, respectively, p = 0.010). Although the dominant liver tumor size was similar, the average number of liver tumors was 4 in the surgical group and 10 in the systemic therapy group (p < 0.0001). The median survival after diagnosis of liver metastases was 35 months in the surgical group and 15 months in the systemic therapy group (p ≤ 0.0001). Five-year survival was zero in the systemic therapy group and 22 % in the surgical group. CONCLUSIONS: This study shows that surgical treatment of liver metastases in selected patients with uveal melanoma, who have limited liver tumor burden and a long interval to metastases development, may result in long-term survival.
BACKGROUND: Although uveal melanoma is a rare disease, its metastasis to the liver is associated with a poor survival. The aim of this study is to analyze the survival after surgical treatment of uveal melanoma metastases to the liver. METHODS: Within 15 years, 44 patients with uveal melanoma metastases to the liver were managed at a single center. Medical records were reviewed to identify patients who underwent surgical treatment of their liver disease. Clinical and oncologic results were compared to those patients who were managed otherwise. T test, Chi-square test, and Kaplan-Meier survival analyses were performed. RESULTS: There were 16 patients who underwent surgical treatment (laparoscopic liver resection, n = 2 and laparoscopic radiofrequency ablation, n = 14), compared to 28 patients who received systemic therapy. The groups were similar regarding demographics and size of primary tumor. The interval between diagnoses of primary tumor and liver metastases was longer for the surgical group (58 vs 22 months, respectively, p = 0.010). Although the dominant liver tumor size was similar, the average number of liver tumors was 4 in the surgical group and 10 in the systemic therapy group (p < 0.0001). The median survival after diagnosis of liver metastases was 35 months in the surgical group and 15 months in the systemic therapy group (p ≤ 0.0001). Five-year survival was zero in the systemic therapy group and 22 % in the surgical group. CONCLUSIONS: This study shows that surgical treatment of liver metastases in selected patients with uveal melanoma, who have limited liver tumor burden and a long interval to metastases development, may result in long-term survival.
Authors: Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Barbara S Hawkins; James A Hayman; Ishmael Jaiyesimi; Lee M Jampol; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Bradley R Straatsma; Jonni Thoma Journal: Arch Ophthalmol Date: 2005-12
Authors: D Gomez; C Wetherill; J Cheong; L Jones; E Marshall; B Damato; S E Coupland; P Ghaneh; G J Poston; H Z Malik; S W Fenwick Journal: J Surg Oncol Date: 2013-12-19 Impact factor: 3.454
Authors: P Mariani; S Piperno-Neumann; V Servois; M G Berry; T Dorval; C Plancher; J Couturier; C Levy-Gabriel; L Lumbroso-Le Rouic; L Desjardins; R J Salmon Journal: Eur J Surg Oncol Date: 2009-03-28 Impact factor: 4.424
Authors: Michael Tsinberg; Gurkan Tellioglu; Conrad H Simpfendorfer; R M Walsh; Matthew R Walsh; David Vogt; John Fung; Eren Berber Journal: Surg Endosc Date: 2008-12-31 Impact factor: 4.584
Authors: Thomas M Aaberg; Kyle R Covington; Tony Tsai; Yevgeniy Shildkrot; Kristen M Plasseraud; Katherina M Alsina; Kristen M Oelschlager; Federico A Monzon Journal: Ocul Oncol Pathol Date: 2020-07-06